Fig. 4From: The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling studyResults by ART status amongst individuals not receiving IPT during the CORTIS-HR study. Points show median model output, bars show 95% range of model outputs. Colours indicate ART status (see key). Top row: ratio of cases averted (compared to universal treatment). Second row: cumulative number screened. Third row: cumulative number given 3HP. Fourth row: maximum cost of test (relative to 3HP) such that total cost does not exceed cost of universal treatment. Fifth row: maximum cost of test (relative to 3HP) such that cost per case averted does not exceed cost per case averted of universal treatment. Left panel: after 5 years; right panel: after 10 yearsBack to article page